| 摘要: |
| CD30是一种细胞表面抗原，在正常活化的淋巴细胞表面低表达，但是在多种淋巴瘤细胞表面高表达，因此成为治疗淋巴瘤的靶抗原之一。抗体偶联药物维布妥昔单抗与CD30结合后能快速内化进入肿瘤细胞诱导其凋亡，在临床应用中疗效显著。此外，临床研究表明靶向CD30的嵌合抗原受体T细胞治疗具有较好安全性、有效性及患者耐受性，为复发或难治性淋巴瘤患者带来希望。本文就维布妥昔单抗及靶向CD30的嵌合抗原受体T细胞在淋巴瘤治疗中的研究进展进行综述。 |
| 关键词: CD30 维布妥昔单抗 嵌合抗原受体T细胞 靶向治疗 |
| DOI：10.16781/j.CN31-2187/R.20211175 |
| 投稿时间：2021-11-19修订日期：2022-02-21 |
| 基金项目:国家自然科学基金(81770209) |
|
| Brentuximab vedotin and anti-CD30 chimeric antigen receptor-modified T cells in treatment of lymphoma: research progress |
| YE Ming-yu,WANG Tao,YU Jie-chen,YANG Jian-min* |
(Department of Hematology, The First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200433, China
*Corresponding author) |
| Abstract: |
| CD30 is a cell surface antigen with low expression on normal activated lymphocytes but high expression on the surface of various lymphoma cells, so it has become one of the target antigens for lymphoma therapy. The antibody-binding drug brentuximab vedotin can be rapidly internalized into tumor cells to induce apoptosis after binding to CD30, and has a significant curative effect in clinical application. In addition, anti-CD30 chimeric antigen receptor-modified T cell therapy is safe, effective and well tolerated, bringing hope to patients with relapsed/refractory lymphoma. This article reviews the research progress of brentuximab vedotin and anti-CD30 chimeric antigen receptor-modified T cells in the treatment of lymphoma. |
| Key words: CD30 brentuximab vedotin chimeric antigen receptor T cell targeted therapy |
